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ABSTR ACT: Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 
1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) 
may reduce the intracellular concentration of the drug via an active pump mechanism. We thus investigated the correlation between AGP and PGP levels 
and the resistance/response to treatment. A total of 26 CML patients were investigated for AGP and PGP levels at diagnosis and during treatment. There 
was no significant difference or correlation between AGP levels and the different groups of patients. There was also no significant difference in the fluo-
rescence intensities of PGP levels among the different patient groups. The resistance observed in our CML patient population could not be correlated with 
AGP and PGP levels. There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.
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Introduction
Although imatinib mesylate (IM) was shown to be efficacious 
in treating chronic myeloid leukemia (CML) patients,1–3 an 
increasing rate of resistance has been reported not only for 
IM4–12 but also subsequently for other generations of tyrosine 
kinase inhibitors (TKIs).13,14
We previously reported a high rate of resistance to IM that 
reached up to 54% in CML patients in Qatar. We investigated 
the possible mechanism of this high rate of resistance through 
a series of experiments and reported the impact of mutations/
single-nucleotide polymorphisms (SNPs) and additional chro-
mosomal abnormalities (ACAs) on CML resistance to IM.15
While mutations/SNPs explained only 8% of resistant 
cases, ACAs were the most common cause of treatment fail-
ure in 23% of our CML patient cohort; intolerance, on the 
other hand, was further noticed in 8% of patients, and the 
mechanisms of resistance remained unknown in 15% of 
patients.15 Here, we report on our investigation of alpha-1-acid 
 glycoprotein (AGP) and protein glycoprotein (PGP) as the 
possible causes of CML resistance to IM treatment.
Alpha-1-acid glycoprotein. The human serum AGP is pre-
dominantly synthesized in the liver as a single-chain  glycoprotein 
that belongs to the family of acute-phase reactants and is elevated 
in various physiological and pathological conditions.16
The native protein with a molecular weight of 40,000 has 
a low isoelectric point, resulting in a negatively charged mol-
ecule at physiological pH.16
AGP is mainly known to bind basic and neutral drugs 
such as IM to prevent them from binding their targets.16,17
In vitro studies suggested that AGP binds IM at physiologi-
cal concentrations and blocks the inhibition of BCR-ABL1.18,19 
Yet, even at supraphysiological concentrations, several groups 
reported that AGP could not inhibit the cytotoxic influence of 
IM on K562 cells.20–22
On the other hand, many in vivo studies reported ele-
vated AGP levels in CML patients. However, none of these 
studies showed a correlation between elevated AGP levels and 
IM resistance.23
We thus explored if AGP levels correlate with the high 
rate of resistance in our cohort of CML patients.
Protein glycoprotein. As another possible cause of 
resistance, we investigated the 170–180 kDa transmembrane 
cluster of differentiation (CD243) PGP protein that belongs 
to the multidrug resistance 1 (MDR-1) family. It may induce 
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resistance via reducing the intracellular concentration of IM,24 
and its overexpression has been frequently implicated in tumor 
resistance to different chemotherapeutic drugs.25–27
This protein carries out an adenosine triphosphate (ATP)-
dependent efflux of structurally diverse lipophilic compounds 
and expels anticancer chemotherapy agents out of cells.28,29
Various authors demonstrated that IM is a substrate of 
PGP and that some aspects of resistance to IM treatment may 
therefore be caused by an increased PGP activity.30–32
In vitro generated models of resistant CML (LAMA84-R) 
cell lines showed overexpression of PGP and BCR-ABL1.33
Therefore, we also investigated the correlation between 
PGP levels and the high resistance to IM treatment in our 
CML patients.
Design and Methods
Patient recruitment. Patients aged 16–65 years with 
philadelphia chromosome positive (Ph+) CML for at least 
12 months and receiving only IM treatment during November 
2006 to December 2011 were included in the study. Patients 
gave their written, informed consent to participate, and blood 
samples were collected. The study was conducted in accor-
dance with the principles of the Declaration of Helsinki, and 
approved by Hamad Medical Corporation Research commit-
tee (HMC research proposal no. 400/06).
Treatment regimen. Patients in the chronic phase (CP) 
received 400 mg of IM orally once daily, while patients in the 
accelerated phase (AP) received 600 mg once daily as per the 
European LeukemiaNet (ELN). Patients’ response to IM was 
assessed according to the ELN 2006, 2009, and 2013 guide-
lines as described previously.34–36
Assessment of patients’ response. Patients’ responses 
based on the absolute quantification of BCR-ABL1 were 
assessed as reported earlier. The BCR-ABL1 kinase domain 
mutations and ACA results are reported elsewhere.15,37
AGP and PGP studies. The levels of AGP and PGP 
were measured in patients treated with IM and compared 
with 10 healthy individuals as a control group.
AGP levels. Serum samples were obtained from patients 
at diagnosis and during treatment. Determination of serum 
AGP levels was carried out by immunoturbidimetric analysis 
in the COBAS INTEGRA® 400 system using the cassette 
COBAS INTEGRA® alpha 1 acid glycoprotein. This assay is 
based on the formation of an AGP precipitate with a specific 
antiserum that could be measured turbidimetrically at 340 nm.
Precinorm and precipath proteins were used as quality con-
trol for monitoring the accuracy and precision of the machine.
The machine was calibrated for the detection of AGP 
using Calibrator For Automated Systems (C.F.A.S) protein 
(normal range 0.5–1.20 g/L).
Pearson correlation coefficient was used to examine the 
linear relationship between AGP, platelets (PLTs), white blood 
cells (WBCs), absolute basophils (Abs. Baso), and lactate 
dehydrogenase (LDH) during different stages of the disease.
PGP levels. Peripheral blood and bone marrow samples 
were collected in ethylenediaminetetraacetic acid (EDTA) to 
study the PGP levels. Total WBCs were collected and washed 
in 1× phosphate-buffered saline (PBS) and adjusted to 5 × 103 
to -2 × 104 cells/μL in PBS. Then, 100 μL of cell suspension 
was incubated for 15 minutes at room temperature with 20 μL 
7-aminoactinomycin D (7AAD), 20  μL monoclonal anti-
body (MAb) CD243-phycoerythrin (PE) conjugated, 20 μL 
CD34-fluorescein isothiocyanate (FITC), and 10 μL CD45 
phycoerythrin-Texas Red conjugate (energy coupled dye) ECD 
(Beckman Coulter). For negative control, cells were incubated 
with 10 μL Immunoglobulin IgG2a-phycoerythrin-cyanine5 
conjugate PC5, 20 μL mouse IgG2a-PE, 20 μL IgG1-FITC, 
and 10 μL IgG2-ECD (Beckman Coulter).
To further purify the sample, red blood cells were lysed 
using VersaLyse™ reagent (Beckman Coulter), by adding 
1 mL of red blood lysis buffer and incubating at room tem-
perature for 10 minutes. Cells were then centrifuged twice at 
300× g for five minutes, supernatant was discarded, and the 
WBC pellet was resuspended in 0.5 mL PBS.
Lyophilized human lymphocytes were used to establish 
and adjust four-color compensation settings, and PGP expres-
sion was gated on viable WBCs.
The samples were processed in an FC 500 flow cytometer 
(Beckman Coulter), and data were collected using four colors, 
one laser protocol in list Mode data files. 7AAD was mea-
sured on FL4 detector, PGP labeling was measured on FL2 
detector, CD34 was measured on FL1 detector, and CD45 
was measured on FL3 detector. Forward scatter and side scat-
ter (SSC) were collected using linear scales, and fluorescence 
signals were collected using logarithmic scales. Data acquisi-
tion and analysis were performed on 10,000 viable cells with 
the CXP analysis software package (Beckman Coulter).
The logarithmically amplified signals were converted 
to linear values, which refer to the dynamic range of signal 
intensities (1–10,000). The differences in fluorescence inten-
sity between isotypic controls and test samples were measured. 
PGP results were expressed as a ratio of arithmetic mean 
fluorescence intensity of CD243 MAbs/arithmetic mean fluo-
rescence intensity of isotypic control. This technique was opti-
mized and adopted from University College London protocols.
Results
Patients recruited into the study. The clinical profiles of 
patients were reported elsewhere.15
A total of 40 patients with CML presented to the 
National Centre for Cancer Care and Research (NCCCR) 
between November 2006 and December 2011. Among them, 
33 patients (27 males, 6 females, median age 40.5 years (range: 
16–62 years); 28 patients in CP and 5 in AP) met the inclusion 
criteria and were recruited into the study.
Due to multiethnic nature of Qatar, 7 patients were 
lost to follow-up because they traveled back to their home 
countries during the first three months of diagnosis, leaving 
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only 26 patients in the study. Of the 26 patients, 22 (P1–P8, 
P10–P22, P25, and P31) were in CP and 4 (P5, P9, P23, and 
P26) in AP.
Twelve patients (P1, P2, P5, P7, P9, P10, P14, P17, P20, 
P23, P25, and P26) responded optimally, and 14 patients (P3, 
P4, P6, P8, P11–P13, P15, P16, P18, P19, P21, P22, and P31) 
failed treatment (failure and suboptimal response), as reported 
previously.15
Of the 14 patients who failed treatment, 12 (P3, P7, P8, 
P12, P13, P15, P16, P18, P19, P21, P22, and P31) resisted 
the drug and 2 (P4 and P11) did not tolerate it. Of the 
12 patients, patient P22 had E459K mutation and patient P3 
showed both ACAs and an insertion mutation. Other com-
monly reported mutations were not present in our cohort of 
patients. Six patients (P7, P8, P12, P19, P21, and P31) had 
ACAs, four (P13, P15, P16, and P18) had no identifiable 
underlying mechanisms of resistance, and three (P7, P12, and 
P21) died of disease progression.15
Molecular monitoring and patients’ response. Patients 
were followed up every 3 months until the end of the study, 
and all the 12 responders achieved a major molecular response 
(MMR) at 12 months onward.
On the other hand, of the 14 patients who failed treatment, 
8 did not achieve MMR and 6 had primary resistance to IM and 
showed neither hematological nor cytogenetic response. These 
14 patients were switched to next-generation TKIs, and no fur-
ther data could be collected due to ethical approval limitations.
AGP results.
At diagnosis. Of the 22 CP patients, 11 (P1–P4, P6–P8, 
and P10–P13) had elevated AGP (mean 1.2 (±0.12) g/L) and 
3 (P5, P9, and P23) of the 4 AP patients had elevated AGP 
(mean 1.61 (±0.38) g/L; Fig. 1).
During follow-up. The mean AGP level among the 14 
patients who failed treatment (resistant group) was 1.05 
(±0.09)  g/L, while the mean level for the 12 patients who 
responded optimally (optimal responders group) was nonsig-
nificantly higher at 1.1 (±0.06) g/L (Fig. 1).
Of the 14 resistant patients who had mutations/ACAs, 
8 (P3, P7, P8, P12, P19, P21, P22, and P31) showed a mean 
AGP level of 1.06 (±0.09) g/L, while 6 (P4, P11, P13, P15, 
P16, and P18) of the 14 patients with no mutations/ACAs 
showed no significant difference in the AGP level of 1.04 
(±0.08) g/L.
There were also no significant differences between AGP 
levels in six patients (P7, P8, P12, P19, P21, and P3) who had 
ACAs and the two patients (P3 and P22) who had the mutations.
The mean AGP level of healthy individuals was 0.75 g/L 
(0.47–1.0 g/L). This level was significantly lower when compared 
with different patient groups (Fig. 1). However, among the dif-
ferent groups of patients, there were no significant differences.
Nonetheless, the group that failed treatment showed a 
strong correlation between AGP and LDH (P  =  0.0001), 
WBCs (P = 0.002), and Abs. Baso (P = 0.03; Table 1).
PGP results. The mean PGP levels were 1.25 (±0.06), 
1.17 (±0.02), 1.21 (±0.03), and 1.2 (±0.04) g/L for AP, CP, 
optimal responders, and resistant group, respectively. Flow 
cytometric analysis showed no significant difference in the 
fluorescence intensities of blast cells incubated with CD243 
and blast cells incubated with isotypic control among the dif-
ferent diseased groups. (Figs. 2 and 3).
There was also no significant difference in the fluores-
cence intensities of blast cells between patients who had ACAs 
and patients who had SNPs/mutations. &3 $3 5HVLVWDQWJURXS 2SWLPDOUHVSRQGHU &RQWURO &0/JURXSV7KHPHDQ$*3OHYHOJ/
Figure 1. mean aGP levels for different groups of CmL patients.
Notes: The mean aGP levels were 1.2 (±0.12), 1.61 (±0.38), 1.05 (±0.09), 
1.1 (±0.06), and 0.71 (±0.04) g/L for 22 CP, 4 aP, 14 resistant group,  
12 optimal responders, and control group of patients, respectively, and the 
differences between the diseased group and the control group, on other 
hand, were significant (P = 0.001, 0.03, 0.003, and 0.005, respectively).
Table 1. relationship between aGP and other markers in CmL 
patients.
AGP LEVEL
CML
GROUPS
CORRELATION 
COEFFICIENT
BIOMARKERS
SIGNIFICANT 
CORRELATION
PLTs WBCs Abs.  
Baso
LDH
CP
r = -0.56 -0.24 -0.32 0.35
P = 0.19 0.52 0.39 0.35
aP
r = -0.3 -0.80 -0.23 -0.89
P = 0.61 0.1 0.70 0.04
resistant  
group
r = 0.47 0.70 0.53 0.86
P = 0.06 0.002 0.03 0.0001
optimal  
responders
r = -0.069 -0.47 0.13 0.07
P = 0.80 0.20 0.72 0.87
Notes: Pearson correlation of aGP and PLTs, WBCs, abs. Baso, and LDH. 
No correlation could be identified between AGP and other biomarkers of 
CmL patients in the group that responded optimally to treatment (optimal 
responders). However, the group that failed treatment (resistant group) 
showed a strong correlation between aGP and LDH (P = 0.0001), WBCs 
(P = 0.002), and abs. Baso (P = 0.03). Pearson correlation coefficient (r), 
significant correlation values (P).
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Figure 2. mean results of PGP/control ratio of different CmL groups.
Notes: The mean PGP expression levels were 1.25 (±0.06), 1.17 (±0.02), 
1.21 (±0.03), and 1.2 (±0.04) for aP, CP, optimal responders, and 
resistant groups, respectively.$ %ODVW 0RQR/\PSK 9LDEOH 1RQYLDEOH %1HXWUR66& &'(&' $$' &'3(           66& % &%OJ*D3( &'FRQWUROUDWLR&'  ('
Figure 3. PGP expression using flow cytometry.
Notes: (A) Differentiation of WBC population using CD45 eCD antibody/ssC, (B) discrimination of viable and nonviable cells by 7aaD antibody/ssC,  
(C) CD243 on viable blast cells, (D) isotypic control on blast cells, and (E) difference between the fluorescence intensities of blast cells incubated with 
CD243 and blast cells incubated with isotypic control (CD243/control ratio).
Discussion and Conclusion
AGP is an acute-phase protein that has been proposed to 
promote CML resistance to IM.18 In this study, the protein 
levels were correlated with different stages of the disease and 
did not show any significant correlation between AGP and 
disease response or progression. Our results comply with those 
reported by Jorgensen et al and le Coutre et al who showed 
that supraphysiological levels of AGP did not result in CML 
resistance to IM in animal models.22,23
Our results showed a moderate-to-strong correlation 
between AGP and other CML markers, namely, WBCs, 
Abs. Baso, and LDH, suggesting that AGP as an acute-phase 
protein might behave as a marker that reflects disease status 
rather than being a cause of resistance to treatment. The cor-
relation between AGP and PLTs might become significant in 
larger cohorts of patients.
On the other hand, PGP expression did not show any 
correlation with the disease stage or other markers of disease. 
Our results in this regard comply with the study carried out by 
Weisberg and Griffin.38
There was a significant difference in the AGP levels 
between the patient group and the control group; however, 
there was no significant difference in AGP levels among the 
different groups of patients.
Combining AGP with other markers showed signifi-
cant correlations during different disease stages that may be 
employed as a warning sign for resistance of CML to TKIs.
PGP expression, on the other hand, did not differ in 
patients presenting in CP or AP and showed no specific pat-
tern among those who resist or respond to IM treatment.
Impact of presence of alpha acid glycoprotein and protein glycoprotein 
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The resistance observed in our CML patient population 
could not be correlated with AGP and PGP levels. There was 
also no significant pattern of AGP and PGP expression, irre-
spective of the response or resistance to treatment.
Acknowledgments
The authors would like to thank the Qatar National Research 
Fund (QNRF) for sponsoring this research project, the hema-
tology team at the National Center for Cancer Care and 
Research (NCCCR) of Hamad Medical Corporation (HMC) 
for recruiting CML patients, and Dr Rajvir Singh for his 
assistance in statistical analysis.
Author Contributions
Designed the project, carried out the experiments, inter-
preted and analyzed the results, and wrote the manuscript: 
NIA-D. Provided clinical data: MAY. Supervised the prog-
ress of experiments: HMM. Critically revised the manuscript: 
HMM, APJ and MAY. All the authors read and approved the 
final manuscript.
REFERENCES
 1. Nair V, Sharma A, Kotwal J, et al. Monitoring of response to therapy with ima-
tinib mesylate in chronic myeloid leukemia in chronic phase (CML-CP). Med J 
Armed Forces India. 2014;70(4):315–320.
 2. Sánchez-Guijo FM, Durán S, Galende J, et al. Evaluation of tolerability and effi-
cacy of imatinib mesylate in elderly patients with chronic phase CML: ELDER-
GLI study. Leuk Res. 2011;35(9):1184–1187.
 3. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed 
patients with chronic myeloid leukemia: incidence of sustained responses in an 
intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358–3363.
 4. Druker BJ, Guilhot F, O’Brien SG, et al; IRIS Investigators. Five-year follow-
up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 
2006;355(23):2408–2417.
 5. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and sec-
ondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009; 
16(2):122–131.
 6. Deininger M. Resistance to imatinib: mechanisms and management. J Natl 
Compr Canc Netw. 2005;3(6):757–768.
 7. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to ima-
tinib mesylate. Methods Mol Med. 2006;125:93–106.
 8. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of 
BCR-ABL mutations in patients with chronic myeloid leukemia treated with 
imatinib mesylate. Leukemia. 2006;20(10):1767–1773.
 9. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase 
chronic myeloid leukemia patients with up-front cytogenetic resistance to ima-
tinib are associated with a greater likelihood of progression to blast crisis and 
shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid 
Leukemia. J Clin Oncol. 2005;23(18):4100–4109.
 10. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal 
evolution in patients with chronic myelogenous leukemia on imatinib mesylate 
therapy. Blood. 2003;101(10):3794–3800.
 11. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolu-
tion of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76–94.
 12. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase 
responding to imatinib: the occurrence of additional cytogenetic abnormalities 
predicts disease progression. Haematologica. 2003;88(3):260–267.
 13. Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in 
chronic myeloid leukemia and recent therapeutic strategies to overcome resis-
tance. Hematology Am Soc Hematol Educ Program. 2009;(1):461–476.
 14. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-
generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009; 
15(24):7519–7527.
 15. Al-Dewik NI, Jewell AP, Yassin MA, El-Ayoubi HR, Morsi HM. Studying the 
impact of presence of point mutation, insertion mutation and additional chromo-
somal abnormalities in chronic myeloid leukemia patients treated with imatinib 
mesylate in the State of Qatar. QSci Connect. 2014;2014(1):13.
 16. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glyco-
protein in health and disease. Pharmacol Rev. 1988;40(1):1–47.
 17. Meijer DK, van der Sluijs P. Binding of drugs to alpha 1-acid glycoprotein and 
its desialylated form. Influence on hepatic disposition and implications for drug 
targeting to the liver. Prog Clin Biol Res. 1989;300:143–167.
 18. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glyco-
protein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl 
inhibitor STI571. J Natl Cancer Inst. 2000;92(20):1641–1650.
 19. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of 
the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and 
pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem 
Pharmacol. 2003;66(10):1907–1913.
 20. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-
positive stem cells from patients with chronic myeloid leukemia are insensitive to 
STI571 in vitro. Blood. 2002;99(1):319–325.
 21. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional 
ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by ima-
tinib mesylate. Blood. 2006;108(4):1370–1373.
 22. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. 
Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia 
patients does not mediate significant in vitro resistance to STI571. Blood. 2002; 
99(2):713–715.
 23. le Coutre P, Kreuzer KA, Na IK, et al. Determination of alpha-1 acid glycoprotein 
in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of ther-
apy with STI571. Blood Cells Mol Dis. 2002;28(1):75–85.
 24. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance 
to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368–2373.
 25. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in 
Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162.
 26. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-
dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
 27. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. 
Annu Rev Pharmacol Toxicol. 1999;39:361–398.
 28. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular 
basis for poly-specific drug binding. Science. 2009;323(5922):1718–1722.
 29. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by 
the multidrug transporter. Annu Rev Biochem. 1993;62:385–427.
 30. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyro-
sine kinase inhibitors with the human multidrug transporter proteins, MDR1 
and MRP1. Biochim Biophys Acta. 2002;1587(2–3):318–325.
 31. Ferrao PT, Frost MJ, Siah SP, Ashman LK. Overexpression of P-glycoprotein in 
K562 cells does not confer resistance to the growth inhibitory effects of imatinib 
(STI571) in vitro. Blood. 2003;102(13):4499–4503.
 32. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into 
and out of cells: implications for drug resistance. Blood. 2004;104(12):3739–3745.
 33. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization 
of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase 
inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070–1079.
 34. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S, European 
Leukemia N. Response definitions and European Leukemianet Management 
recommendations. Best Pract Res Clin Haematol. 2009;22(3):331–341.
 35. Baccarani M, Saglio G, Goldman J, et al; European LeukemiaNet. Evolving concepts 
in the management of chronic myeloid leukemia: recommendations from an expert 
panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–1820.
 36. Haznedaroglu IC. Current concerns of undertreatment and overtreatment in 
chronic myeloid leukemia based on European LeukemiaNet 2013 recommenda-
tions. Expert Opin Pharmacother. 2013;14(15):2005–2010.
 37. Al-Dewik NI, Jewell AP, Yassin MA, El-Ayoubi HR, Morsi HM. Molecular mon-
itoring of patients with chronic myeloid leukemia (CML) in the state of qatar: opti-
mization of techniques and response to imatinib. QSci Connect. 2014;2014(1):24.
 38. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical 
mechanisms. Drug Resist Updat. 2003;6(5):231–238.
